Literature DB >> 27886697

Nonsurgical Management of Osteoarthritis Knee Pain in the Older Adult.

Nora Taylor1.   

Abstract

Symptomatic knee osteoarthritis is a common complaint of many elderly patients in primary care offices. For those unable or unwilling to undergo knee replacement, the primary practitioners' understanding of the strengths and weaknesses of the available treatment modalities for pain relief is critical to successful in-office counseling and expectation management. Treatment requires a multimodal approach of nonpharmacologic and pharmacologic therapies to achieve a maximal clinical benefit. The focus of this review is on the nonsurgical options for treatment of knee osteoarthritis in patients aged 65 and older. Copyright Â
© 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Management; Nonpharmacologic; Osteoarthritis; Pharmacologic

Mesh:

Year:  2016        PMID: 27886697     DOI: 10.1016/j.cger.2016.08.004

Source DB:  PubMed          Journal:  Clin Geriatr Med        ISSN: 0749-0690            Impact factor:   3.076


  9 in total

1.  Effectiveness of a novel hydrolyzed collagen formulation in treating patients with symptomatic knee osteoarthritis: a multicentric retrospective clinical study.

Authors:  Piero Volpi; Raul Zini; Franz Erschbaumer; Michelangelo Beggio; Alberto Busilacchi; Giulia Carimati
Journal:  Int Orthop       Date:  2020-05-23       Impact factor: 3.075

Review 2.  Effects of motor imagery on strength, range of motion, physical function, and pain intensity in patients with total knee arthroplasty: A systematic review and meta-analysis.

Authors:  Raúl Ferrer-Peña; Ferran Cuenca-Martínez; Mario Romero-Palau; Luis Miguel Flores-Román; Pablo Arce-Vázquez; Clovis Varangot-Reille; Luis Suso-Martí
Journal:  Braz J Phys Ther       Date:  2021-11-30       Impact factor: 3.377

3.  lncRNA SNHG16 promotes the occurrence of osteoarthritis by sponging miR‑373‑3p.

Authors:  Haiyan Fan; Liangjia Ding; Yun Yang
Journal:  Mol Med Rep       Date:  2020-12-10       Impact factor: 2.952

4.  Continuous care intervention with carbohydrate restriction improves physical function of the knees among patients with type 2 diabetes: a non-randomized study.

Authors:  Kade S Lyman; Shaminie J Athinarayanan; Amy L McKenzie; Camy L Pearson; Rebecca N Adams; Sarah J Hallberg; James P McCarter; Jeff S Volek; Stephen D Phinney; John P Andrawis
Journal:  BMC Musculoskelet Disord       Date:  2022-03-29       Impact factor: 2.362

5.  Methylene blue relieves the development of osteoarthritis by upregulating lncRNA MEG3.

Authors:  Xinyi Li; Chaoliang Tang; Jin Wang; Peipei Guo; Chengyao Wang; Yanlin Wang; Zongze Zhang; Huisheng Wu
Journal:  Exp Ther Med       Date:  2018-03-02       Impact factor: 2.447

6.  Long non-coding RNA DANCR regulates proliferation and apoptosis of chondrocytes in osteoarthritis via miR-216a-5p-JAK2-STAT3 axis.

Authors:  Lei Zhang; Pin Zhang; Xiangyi Sun; Liwu Zhou; Jianning Zhao
Journal:  Biosci Rep       Date:  2018-12-14       Impact factor: 3.840

7.  Long Non-Coding RNA (LncRNA) CAIF is Downregulated in Osteoarthritis and Inhibits LPS-Induced Interleukin 6 (IL-6) Upregulation by Downregulation of MiR-1246.

Authors:  Ke Qi; Rongqiang Lin; Chenchen Xue; Tianze Liu; Yiming Wang; Yongjin Zhang; Jia Li
Journal:  Med Sci Monit       Date:  2019-10-26

8.  Knockdown of exosome‑mediated lnc‑PVT1 alleviates lipopolysaccharide‑induced osteoarthritis progression by mediating the HMGB1/TLR4/NF‑κB pathway via miR‑93‑5p.

Authors:  Yong Meng; Siqiang Qiu; Long Sun; Jinliang Zuo
Journal:  Mol Med Rep       Date:  2020-10-14       Impact factor: 2.952

9.  Effectiveness and safety of polydioxanone thread-embedding acupuncture (TEA) and electroacupuncture (EA) treatment for knee osteoarthritis (KOA) patients with postoperative pain: An assessor-blinded, randomized, controlled pilot trial.

Authors:  Ye Ji Lee; Chang-Hyun Han; Ju Hyun Jeon; Eunseok Kim; Jin Youp Kim; Ki Hyun Park; Ae Ran Kim; Eun Jung Lee; Young Il Kim
Journal:  Medicine (Baltimore)       Date:  2020-07-24       Impact factor: 1.817

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.